바로가기
본문 바로가기
메인메뉴 바로가기
CGRL
Cancer Genomics
Research Laboratory

Clinical Research

Home > PUBLICATIONS > Clinical Research

No. Journal File
36
 Lim KH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ., Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2011 Oct;68(4):1017-26.
35
 Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG., Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2011 Oct;68(4):1045-55.
34
 Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, Kim TY, Pover GM, Morris CD, Douillard JY., A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs. 2011 Oct;29(5):1021-8.
33
 Han W, Woo JH, Jeon YK, Yang SJ, Cho J, Ko E, Kim TY, Im SA, Oh DY, Park IA, Hwang KT, Moon HG, Yang KS, Noh DY., 17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy. Experimental and Therapeutic Medicine (Exp Ther Med.). 2011 Sep;2(5):799-804.
32
 Koh Y, Lee HE, Im SA, Kim SH, Kim TM, Han SW, Oh DY, Kim JH, Lee SH, Kim DW, Kim TY, Kim WH, Heo DS, Bang YJ., VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. Diagnostic Molecular Pathology. 2011 Sep;20(3):143-7.
31
 Keam B, Im SA, Park S, Nam BH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ., Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. J Cancer Res Clin Oncol. 2011 Sep;137(9):1301-8.
30
 Bae JM, Kim MJ, Kim JH, Koh JM, Cho NY, Kim TY, Kang GH., Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Arch. 2011 Jul;459(1):55-63.
29
 Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY, Bang YJ., Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. CANCER SCIENCE. 2011 Jul;102(7):1388-95
28
 Shin DY, Han SW, Oh DY, Im SA, Kim TY, Bang YJ., Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2011 Jul;68(1):165-75.
27
 Im SA, Kim JW, Kim JS, Kim MA, Jordan B, Pickl M, Han SW, Oh DY, Lee HJ, Kim TY, Kim WH, Yang HK, Bang YJ., Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol. 2011 Jun;20(2):94-100.
26
 Kim K, Chie EK, Han W, Noh DY, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW., Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. Tumori. 2011 May-Jun;97(3):280-5.
25
 Baek SK, Han SW, Oh DY, Im SA, Kim TY, Bang YJ., Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer. BMC Gastroenterol. 2011 May 19;11:56.
24
 Lee YG, Han SW, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Ha SW, Bang YJ. , Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection. BMC CANCER. 2011 May 21;11:188.
23
 Kim JW, Lee JO, Han SW, Oh DY, Im SA, Kim TY, Bang YJ., Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy. Am J Clin Oncol. 2011 Apr;34(2):125-9. 2010 Mar 19. [Epub ahead of print]
22
 Kim H, Han W, Moon HG, Min J, Ahn SK, Kim TY, Im SA, Oh DY, Han SW, Chie EK, Ha SW, Noh DY., The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma. Breast Cancer Res Treat. 2011 Apr;126(3):637-41.
21
 Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ., Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011 Mar 2;13(2):R22.
20
 Nam HJ, Kim HP, Yoon YK, Hur HS, Song SH, Kim MS, Lee GS, Han SW, Im SA, Kim TY, Oh DY, Bang YJ., Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. CANCER LETTERS. 2011 Mar 28;302(2):155-65.
19
 Ku JL, Kim KH, Choi JS, Jeon YK, Kim SH, Shin YK, Kim TY, Bang YJ, Kim WH, Park JG. , Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes. Cellular Oncology (Dordr). 2011 Feb;34(1):45-54.
18
 Kim K, Chie EK, Han W, Noh DY, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW., Age <40 Years is an independent prognostic factor predicting inferior overall survival in patients treated with breast conservative therapy. Breast Journal. 2011 Jan;17(1):75-8.
17
 Choi H, Chun YS, Kim TY, Park JW., HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin. CANCER RESEARCH. 2010 Dec 15;70(24):10101-11.
이전페이지 1 2 3 4 5 6 다음페이지